Wuzi Yanzong Pill for the treatment of male infertility

Abstract Background In Hong Kong, one of six couples is affected by subfertility problems. Male infertility contributes to half of the infertility cases. In male infertility, there is no effective treatment on patients with idiopathic infertility/poor semen parameters. Recent meta-analysis suggests that a traditional Chinese medicine formula — Wuzi Yanzong Pill showed the curative effect on male fertility. However, the heterogeneity of the studies could not draw a definitive conclusion on the therapeutic effect of this formula. The aim of this study is to conduct a well-designed randomized controlled trial to investigate the effect of Traditional Chinese Medicine formula Wuzi Yanzong Pill on improving semen qualities in men with sub-optimal parameters. Methods This study is a double-blinded, randomized placebo-controlled trial conducted in a public hospital in Hong Kong. Participants will be randomized 1:1 ration either the Wuziyanzong Pill formula group or the placebo group using the computer-generated random number. Both groups will administrate the drugs for 12 weeks. Participants will have total four visits for their semen and blood assessments for a six-month period and we will follow up for another six months to record their conception outcome. The primary outcome is to compare the total motile sperm count, natural conception rate and pregnancy outcome to that under placebo treatment. Secondary objects are sperm functions and assisted reproductive technology outcome. Discussion To date, there are none of the studies using the disclosed Wuzi Yanzong formula nor double-blinded, randomized trials. The Wuzi Yanzong TCM formula may provide a good clinical solution for subfertile males that contemporary western medicine has no cure. Therefore, a well-designed randomized trial for evaluating the effect of Wuzi Yanzong TCM formula is urgently needed. Trial registration: Chinese Clinical Trial Registry (ChiCTR), ChiCTR-INR-17010790 Registered on 27/02/2017. http://www.chictr.org.cn/showproj.aspx?proj=18356 Centre for Clinical Research and Biostatistics, Clinical Trials Registry, CUHK_CCRB00548. Registered on 27/02/2017. https://www2.ccrb.cuhk.edu.hk/registry/public/437

Download Full-text

Wuzi Yanzong Pill—Based on Network Pharmacology and In Vivo Evidence—Protects Against Spermatogenesis Disorder via the Regulation of the Apoptosis Pathway

Frontiers in Pharmacology ◽

10.3389/fphar.2020.592827 ◽

2020 ◽

Vol 11 ◽

Author(s):

Wang-qiang Chen ◽

Cai-fei Ding ◽

Jia Yu ◽

Chen-ye Wang ◽

Ling-yi Wan ◽

...

Keyword(s):

Male Infertility ◽

Sperm Quality ◽

Chemical Characterization ◽

Negative Ion ◽

Network Pharmacology ◽

Apoptosis Pathway ◽

Pathway Network ◽

Flight Mass Spectrometry ◽

Wuzi Yanzong Pill

The crisis of male infertility is an issue of human reproductive health worldwide. The Wuzi Yanzong pill (WZYZP) is a traditional Chinese medicine prescription that shows efficacy in kidney reinforcement and essence benefit to ameliorate male reproductive dysfunctions. However, the pharmacological mechanisms of the WZYZP on male infertility have not been investigated and clarified clearly. This study was designed to investigate the effects of the WZYZP on spermatogenesis disorder and explore its underlying pharmacological mechanisms. First, based on a network pharmacology study, 39 bioactive compounds and 40 targets of the WZYZP associated with spermatogenesis disorder were obtained, forming a tight compound-target network. Molecular docking tests showed tight docking of these compounds with predicted targeted proteins. The protein–protein interaction (PPI) network identified TP53, TNF, AKT1, Bcl-XL, Bcl-2, and IκBA as hub targets. The Kyoto Encyclopedia of Genes and Genomes pathway network and pathway-target-compound network revealed that the apoptosis pathway was enriched by multiple signaling pathways and multiple targets, including the hub targets. Subsequently, the chemical characterization of WZYZP was analyzed using liquid chromatography to quadrupole/time-of-flight mass spectrometry, and 40 compounds in positive ion mode and 41 compounds in negative ion mode in the WZYZP were identified. Furthermore, based on the prediction of a network pharmacology study, a rat model of spermatogenesis disorder was established to evaluate the curative role and underlying mechanisms of the WZYZP. The results showed that WZYZP treatment improved rat sperm quality and attenuated serum hormone levels, reversed histopathological damage of the testis, reduced cell apoptosis in testis tissues, and ameliorated the expression of the predicted hub targets (TP53, TNF-α, AKT1, NFκB, and IκBA) and the apoptosis related proteins (Bcl-XL, Bcl-2, Bax, Caspase 3, and Caspase 9). These results indicated that the WZYZP has a protective effect on spermatogenesis disorder, suggesting that it could be an alternative choice for male infertility therapy.

Download Full-text

A double-blinded, randomized placebo-controlled trial on the effect of Traditional Chinese Medicine formula Wuzi Yanzong Pill on improving semen qualities in men with sub-optimal parameters

10.21203/rs.2.500/v2 ◽

2019 ◽

Author(s):

Mingpeng Zhao ◽

Carol Pui Shan Chan ◽

Cosy Wing Ching Cheung ◽

Odai Alqawasmeh ◽

Ronald Chi Chiu Wang ◽

...

Keyword(s):

Hong Kong ◽

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Male Infertility ◽

Controlled Trial ◽

Semen Parameters ◽

Optimal Parameters ◽

Chinese Medicine Formula ◽

Double Blinded ◽

Wuzi Yanzong Pill

Abstract Background In Hong Kong, one of six couples is affected by subfertility problems. Male infertility contributes to half of the infertility cases. In male infertility, there is no effective treatment on patients with idiopathic infertility/poor semen parameters. Recent meta-analysis suggests that a traditional Chinese medicine formula — Wuzi Yanzong Pill showed the curative effect on male fertility. However, the heterogeneity of the studies could not draw a definitive conclusion on the therapeutic effect of this formula. The aim of this study is to conduct a well-designed randomized controlled trial to investigate the effect of Traditional Chinese Medicine formula Wuzi Yanzong Pill on improving semen qualities in men with sub-optimal parameters. Methods This study is a double-blinded, randomized placebo-controlled trial conducted in a public hospital in Hong Kong. Participants will be randomized 1:1 ration either the Wuziyanzong Pill formula group or the placebo group using the computer-generated random number. Both groups will administrate the drugs for 12 weeks. Participants will have total four visits for their semen and blood assessments for a six-month period and we will follow up for another six months to record their conception outcome. The primary outcome is to compare the total motile sperm count, natural conception rate and pregnancy outcome to that under placebo treatment. Secondary objects are sperm functions and assisted reproductive technology outcome. Discussion To date, there are none of the studies using the disclosed Wuzi Yanzong formula nor double-blinded, randomized trials. The Wuzi Yanzong TCM formula may provide a good clinical solution for subfertile males that contemporary western medicine has no cure. Therefore, a well-designed randomized trial for evaluating the effect of Wuzi Yanzong TCM formula is urgently needed. Trial registration: Chinese Clinical Trial Registry (ChiCTR), ChiCTR-INR-17010790 Registered on 27/02/2017. http://www.chictr.org.cn/showproj.aspx?proj=18356 Centre for Clinical Research and Biostatistics, Clinical Trials Registry, CUHK_CCRB00548. Registered on 27/02/2017. https://www2.ccrb.cuhk.edu.hk/registry/public/437

Download Full-text